Experimental ALS Drug Will Not Be Approved
Medically reviewed by Drugs.com.
By Physician’s Briefing Staff HealthDay Reporter
THURSDAY, Sept. 28, 2023 -- An advisory panel to the U.S. Food and Drug Administration on Wednesday voted resoundingly against recommending a stem cell-based experimental treatment for amyotrophic lateral sclerosis (ALS).
Although the FDA is not bound by the votes of its advisory panels, agency scientists have already penned a scathing review of the drug, called NurOwn. The application from Brainstorm, the company that developed the treatment, was "scientifically incomplete" and "grossly deficient," FDA staff scientists wrote in the review.
Meanwhile, the advisory panel voted 17-1 against the drug to treat ALS. Only a panelist representing patients voted for the medication, while one adviser abstained from voting, the Associated Press reported.
"Creating false hope can be considered a moral injury and the use of statistical magic or manipulation to provide false hope is problematic," said Lisa Lee, Ph.D., a bioethics and research integrity expert from Virginia Tech, who voted against the treatment, the AP reported.
The FDA agreed to convene the advisory panel in response to a 30,000-signature petition from ALS patients and advocates. But a study from Brainstorm involving 200 patients did not show that NurOwn extended life, slowed disease, or improved patient mobility, the AP reported. Not only that, but the Brainstorm application was missing details on manufacturing and quality control.
"It really is a disease that needs a safe and effective treatment and there are a lot of other prospects out there that we need to encourage. Approving one like this would get in the way of that," said Kenneth Fischbeck, M.D., a distinguished investigator in the Hereditary Neurological Diseases branch of the National Institutes of Neurological Disorders and Stroke, the AP reported.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Sociodemographics Tied to Rehab Use During Critical Illness Hospitalization
FRIDAY, May 10, 2024 -- For older adults hospitalized with a stay in the intensive care unit (ICU), social determinants of health (SDOH) are associated with use of skilled...
Breakthrough Gene Therapy Enables Infant Born Deaf to Hear
FRIDAY, May 10, 2024 -- Significant hearing improvements have been achieved in an infant with profound hearing loss due to a biallelic otoferlin gene (OTOF) mutation, according to...
Implantable Continuous Flow Device Feasible for Small Children With Severe Systolic Heart Failure
FRIDAY, May 10, 2024 -- The Jarvik 2015 left ventricular assist device (LVAD) seems promising as an implantable continuous flow device for small children with severe systolic...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.